-- Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with ...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory ...
The last time I spoke about Alpine Immune Sciences, Inc. (ALPN) was when it was gearing up to report additional data from its phase 1/2 RUBY-3 study using povetacicept for the treatment of patients ...
-- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose ...
ALPN-303’s dual BAFF/APRIL blockade, early biomarker and safety signals, monthly dosing and multi-indication potential position it to address unmet needs in autoimmune diseaseDublin, Sept. 25, 2026 ...
The RAINIER trial met its primary endpoint, showing that povetacicept effectively reduces proteinuria in patients with immunoglobulin A nephropathy. Povetacicept, an investigational BAFF (B-cell ...
Vertex Pharmaceuticals VRTX announced that the FDA has accepted its biologics license application (BLA) seeking approval for its investigational candidate, povetacicept, for treating adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results